COMBAT-ARF
Phase 1
Recruiting
- Conditions
- Infectious pulmonary endotheliopathyMedDRA version: 20.0Level: LLTClassification code: 10038696Term: Respiratory failure (excl neonatal) Class: 10038738Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Registration Number
- CTIS2024-512641-16-00
- Lead Sponsor
- Rigshospitalet
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 450
Inclusion Criteria
Adult intensive care patients (aged 18 years or above), Suspected pulmonary infection, Need for mechanical ventilation (< 24hours from time of screening), Endothelial biomarker (sTM) = 4 ng/m
Exclusion Criteria
Withdrawal from active therapy, Septic shock according to Sepsis-3 AND sTM>10 ng/ml, Known hypersensitivity to iloprost or to any of the other ingredients., Previously included in this trial or a prostacyclin trial within 30 days, Life-threatening bleeding defined by the treating physician, Known severe heart failure (NYHA class IV), Suspected acute coronary syndrome, Pregnancy (non-pregnancy confirmed by patient being postmenopausal (age 60 or above) or having a negative urine- or plasma-hCG)
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method